Atul Ltd
Atul Ltd. is a diversified and integrated Indian chemical company (a part of Lalbhai Group, Gujarat). The products of the company are used in various Industries and come mainly under two segments, Life Science Chemicals and Performance and Other Chemicals under 9 Businesses. [1]
Since its incorporation, the company has manufactured many products for the first time in India Dyes including Vat Dyes, crop care chemicals, Phosgene, Carbamite, 2,4-D Acid, para Cresol, tissue culture raised date palms. [2]
- Market Cap ₹ 18,041 Cr.
- Current Price ₹ 6,130
- High / Low ₹ 7,198 / 5,560
- Stock P/E 26.6
- Book Value ₹ 2,113
- Dividend Yield 0.49 %
- ROCE 14.9 %
- ROE 11.5 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
Cons
- Stock is trading at 2.90 times its book value
- The company has delivered a poor sales growth of 11.0% over past five years.
- Company has a low return on equity of 9.23% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2,637 | 2,595 | 2,834 | 3,514 | 4,038 | 4,093 | 3,731 | 5,081 | 5,428 | 4,726 | 5,583 | 6,274 | |
| 2,235 | 2,134 | 2,324 | 3,008 | 3,270 | 3,191 | 2,813 | 4,168 | 4,620 | 4,086 | 4,665 | 5,240 | |
| Operating Profit | 402 | 461 | 510 | 505 | 768 | 902 | 918 | 913 | 807 | 639 | 918 | 1,034 |
| OPM % | 15% | 18% | 18% | 14% | 19% | 22% | 25% | 18% | 15% | 14% | 16% | 16% |
| 9 | 37 | 57 | 30 | 38 | 83 | 109 | 82 | 86 | 65 | 115 | 206 | |
| Interest | 26 | 28 | 25 | 13 | 7 | 9 | 9 | 9 | 8 | 11 | 24 | 17 |
| Depreciation | 60 | 66 | 95 | 110 | 119 | 130 | 136 | 177 | 198 | 243 | 317 | 322 |
| Profit before tax | 326 | 404 | 446 | 412 | 680 | 845 | 882 | 810 | 688 | 451 | 692 | 900 |
| Tax % | 31% | 32% | 28% | 32% | 36% | 21% | 25% | 25% | 26% | 28% | 28% | 23% |
| 240 | 274 | 323 | 281 | 436 | 671 | 660 | 605 | 507 | 324 | 499 | 689 | |
| EPS in Rs | 81.13 | 92.44 | 108.88 | 93.21 | 145.72 | 224.69 | 221.64 | 204.23 | 174.19 | 109.71 | 164.37 | 230.25 |
| Dividend Payout % | 10% | 9% | 9% | 13% | 10% | 12% | 9% | 12% | 19% | 18% | 15% | 13% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 9% |
| 5 Years: | 11% |
| 3 Years: | 5% |
| TTM: | 12% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 9% |
| 5 Years: | 1% |
| 3 Years: | 9% |
| TTM: | 39% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 11% |
| 5 Years: | -8% |
| 3 Years: | -3% |
| 1 Year: | -8% |
| Return on Equity | |
|---|---|
| 10 Years: | 13% |
| 5 Years: | 11% |
| 3 Years: | 9% |
| Last Year: | 11% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 30 | 30 | 30 | 30 | 30 | 30 | 30 | 30 | 30 | 29 | 29 | 29 |
| Reserves | 1,009 | 1,585 | 1,936 | 2,214 | 2,676 | 3,125 | 3,797 | 4,399 | 4,642 | 5,085 | 5,569 | 6,192 |
| 299 | 316 | 168 | 16 | 55 | 108 | 127 | 144 | 52 | 237 | 202 | 183 | |
| 485 | 535 | 591 | 749 | 783 | 880 | 982 | 1,117 | 1,028 | 1,104 | 1,179 | 1,465 | |
| Total Liabilities | 1,823 | 2,465 | 2,724 | 3,009 | 3,543 | 4,144 | 4,935 | 5,690 | 5,752 | 6,455 | 6,980 | 7,870 |
| 514 | 750 | 1,026 | 1,027 | 1,104 | 1,125 | 1,418 | 1,634 | 1,770 | 2,792 | 2,847 | 2,676 | |
| CWIP | 112 | 180 | 59 | 96 | 172 | 368 | 250 | 420 | 1,033 | 281 | 124 | 110 |
| Investments | 66 | 382 | 429 | 470 | 752 | 1,137 | 1,361 | 1,339 | 881 | 1,392 | 1,766 | 2,592 |
| 1,131 | 1,154 | 1,210 | 1,415 | 1,515 | 1,513 | 1,906 | 2,297 | 2,068 | 1,990 | 2,242 | 2,492 | |
| Total Assets | 1,823 | 2,465 | 2,724 | 3,009 | 3,543 | 4,144 | 4,935 | 5,690 | 5,752 | 6,455 | 6,980 | 7,870 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 306 | 401 | 392 | 356 | 404 | 881 | 718 | 231 | 707 | 667 | 603 | 1,023 | |
| -167 | -375 | -175 | -129 | -408 | -782 | -645 | -163 | -469 | -683 | -494 | -891 | |
| -124 | -39 | -212 | -207 | -1 | -111 | -52 | -57 | -257 | 38 | -118 | -98 | |
| Net Cash Flow | 16 | -13 | 5 | 19 | -5 | -11 | 21 | 11 | -20 | 22 | -9 | 34 |
| Free Cash Flow | 111 | 31 | 180 | 213 | 195 | 508 | 396 | -359 | -167 | 164 | 334 | 851 |
| CFO/OP | 95% | 111% | 93% | 91% | 86% | 122% | 100% | 47% | 112% | 121% | 82% | 113% |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 61 | 62 | 67 | 75 | 63 | 64 | 72 | 71 | 57 | 72 | 74 | 74 |
| Inventory Days | 105 | 118 | 107 | 83 | 89 | 93 | 128 | 122 | 101 | 90 | 97 | 90 |
| Days Payable | 69 | 87 | 86 | 93 | 66 | 88 | 121 | 90 | 69 | 84 | 82 | 94 |
| Cash Conversion Cycle | 97 | 93 | 88 | 66 | 86 | 69 | 78 | 103 | 89 | 77 | 89 | 70 |
| Working Capital Days | 50 | 46 | 65 | 76 | 74 | 59 | 65 | 77 | 68 | 69 | 77 | 69 |
| ROCE % | 26% | 26% | 23% | 19% | 27% | 28% | 24% | 19% | 15% | 9% | 13% | 15% |
Insights
In beta| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Export share (sales outside India) % |
|
||||||||||
| Number of brands count |
|||||||||||
| Number of countries served count |
|||||||||||
| Number of customers count |
|||||||||||
| Number of production sites count |
|||||||||||
| Number of products and formulations count |
|||||||||||
| Performance and Other Chemicals segment revenue share % |
|||||||||||
| Captive power plant capacity MW |
|||||||||||
| R&D Expenditure (Percentage of Turnover) % ・Standalone data |
|||||||||||
Extracted by Screener AI
Documents
Announcements
- Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011 2d
-
Announcement under Regulation 30 (LODR)-Change in Management
20 Jul - Dr Dhaval Vashi replaces Dr Prabhakar Chebiyyam as Senior Vice President, Pharmaceuticals, effective July 18, 2026.
- Reg. 34 (1) Annual Report. 17 Jul
- Announcement under Regulation 30 (LODR)-Newspaper Publication 9 Jul
- Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 7 Jul
Annual reports
-
Financial Year 2026
from bse
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
Concalls
-
Apr 2026TranscriptAI SummaryPPT
-
Jan 2026TranscriptAI SummaryPPT
-
Oct 2025TranscriptAI SummaryPPT
-
May 2025TranscriptAI SummaryPPT
-
Jan 2025TranscriptAI SummaryPPT
-
Oct 2024TranscriptAI SummaryPPT
-
May 2024TranscriptAI SummaryPPT
-
Jan 2024TranscriptAI SummaryPPT
-
Oct 2023TranscriptAI SummaryPPT
-
Jul 2023TranscriptAI SummaryPPT
Business Segments[1]
1) Life Science Chemicals (29% in FY26 vs 30% in FY25):
a) Crop Protection - Bulk Actives: [1] [2] The company offers 36 products and 46 formulations across herbicides, insecticides, fungicides, and other crop protection chemicals, serving 224 customers in the Agriculture and Crop Protection Chemicals industries. Key products include 2,4-D, Indoxacarb, and Sulfonylurea herbicides, with a global market share of 13% in 2,4-D and 14% in Indoxacarb as of FY26.